(October 13, 2017, 10:37 AM EDT) -- ALEXANDRIA, Va. — Thirty claims of a patent covering methods of treating arthritis through oral administration of a pharmaceutical comprised of zoledronic acid are “extremely broad,” and the patent’s specification “simply fails to enable their full scope,” a petitioner for post-grant review told the Patent Trial and Appeal Board on Oct. 10 (Grünenthal GmbH v. Antecip Bioventures II LLC, PGR2018-00001, PTAB)....